Resources
23 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 3/29/2024
The Centers for Disease Control and Prevention (CDC) has naloxone trainings and fact sheets available for clinicians. The trainings and fact sheets can help clinicians raise awareness about the benefits of naloxone by talking with patients and their family, friends, and caregivers.
Posted 1/26/2024 (updated 3/28/2024)
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.
Posted 7/28/2023 (updated 3/26/2024)
The toolkit Stimulant Safety: Getting Amped Up to Reduce Harms When Using Stimulants was developed through the CDC-funded National Harm Reduction Technical Assistance Center in collaboration with the NASTAD Drug User Health team and consultants. This resource provides education on the reasons people take stimulants, how to minimize harm, reduce stigma around stimulants, support peoples' positive experiences, the intersection of stimulant use and sexual safety, and much more.
Posted 4/4/2023 (updated 3/27/2024)
The guide from the National Council for Mental Wellbeing aims to support harm reduction organizations operating in virtual environments and summarizes some of the strategies that harm reduction organizations have developed and found to be effective at maintaining connection while doing harm reduction work virtually. Harm reduction continued during the COVID-19 pandemic and organizations effectively changed the way services were delivered, primarily through telework.
Posted 2/28/2023 (updated 3/27/2024)
This study's objective was to develop and validate a survey tool to assess emergency department physician attitudes, clinical practice, and willingness to perform opiate harm reduction interventions. After surveying physicians, most showed they were willing to provide necessary interventions, while few do perform them. Although there was an increased willingness to perform the interventions, a disparity remains.
Posted 11/14/2022 (updated 3/27/2024)
In their new 2022 Clinical Practice Guideline, the Centers for Disease Control and Prevention (CDC) provides updated evidence and research on the risks and benefits of prescription opioids for acute, subacute, and chronic pain. These include dosing strategies, tapering and discontinuation, comparisons with nonopioid pain treatments, and risk mitigation strategies.
Posted 11/1/2022 (updated 3/27/2024)
The webinar held by NASTAD on October 26, 2022, 4:00-5:30pm featured a dynamic discussion on integrating harm reduction principles and practices, including naloxone distribution, safe disposal, and harm reduction supply access, within the community health care setting. Health centers across the country that offer these services as part of comprehensive care shared their experiences and the ways that service expansion can contribute to engagement and care access.
Posted 10/3/2022 (updated 3/27/2024)
Nitazenes are a novel group of powerful illicit synthetic opioids derived from 2-benzylbenzimidazole that have been linked to overdose deaths in several states. Nitazenes were created as a potential pain reliever medication nearly 60 years ago but have never been approved for use in the United States. Laboratory test results indicate that the potency of certain nitazene analogs (e.g., isotonitazene, protonitazene, and etonitazene) greatly exceeds that of fentanyl, whereas the potency of the analog metonitazene is similar to fentanyl.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.